Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc.

Daiichi Sankyo Co., Ltd.Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fullyintegrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold.

The FTC cleared the transaction under the Hart-Scott-Rodino Antitrust Improvement Act. Under the terms of the agreement, Luitpold purchased 100% of PharmaForce stock and the closing was completed on December 29, 2009. The PharmaForce product line will be marketed by Luitpold’s subsidiary, American Regent, Inc.

PharmaForce, Inc., founded in 1999, is focused on the manufacture, development and marketing of difficult to manufacture sterile products and sole source or first-tomarket generic injectable products. PharmaForce, headquartered in Columbus, Ohio, operates out of three facilities, including a 40,000 sq ft cGMP compliant sterile manufacturing facility, a 20,000 sq ft R&D facility, and a 20,000 sq ft facility targeted for API manufacturing.

Mary Jane Helenek, President and CEO of Luitpold said, "The acquisition of PharmaForce is another important step in the implementation of Luitpold's strategic plan to further diversify our product portfolio and generate additional growth for Luitpold and its wholly owned subsidiary, American Regent, Inc. This acquisition provides an immediate expansion of our R&D pipeline, increased manufacturing capacity and establishes a base from which to move forward with different injectable dosage forms to take advantage of the fast growing generic injectable market."

Luitpold's legal and financial advisers on the transaction were Sheppard Mullin Richter & Hampton LLP and Aquilo Partners, LP.

PharmaForce's legal and financial advisers were Bricker & Eckler LLP and William Blair & Company, LLC

About Luitpold Pharmaceuticals, Inc.
Luitpold Pharmaceuticals, Inc., headquartered in Shirley, NY, manufactures and distributes over 65 pharmaceutical products including Venofer® (iron sucrose injection, USP), the leading IV iron therapy in the U.S., through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo group company, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions. Daiichi Sankyo Company, Ltd., established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...